Advances in key areas of research have enabled improved outcomes for patients diagnosed with ovarian cancer in the past three decades. In 2015, this trend was maintained with important progress in areas such as guideline compliance, design of targeted approaches and molecular profiling.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion
Cell Death & Disease Open Access 18 January 2022
-
VISTA expressed in tumour cells regulates T cell function
British Journal of Cancer Open Access 09 November 2018
-
The RNA binding protein SORBS2 suppresses metastatic colonization of ovarian cancer by stabilizing tumor-suppressive immunomodulatory transcripts
Genome Biology Open Access 16 March 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Dottino, J. A., Cliby, W. A., Myers, E. R., Bristow, R. E. & Havrilesky, L. J. Improving NCCN guideline-adherent care for ovarian cancer: value of an intervention. Gynecol. Oncol. 138, 694–699 (2015).
Bristow, R. E. et al. Impact of National Cancer Institute Comprehensive Cancer Centers on ovarian cancer treatment and survival. J. Am. Coll. Surg. 220, 940–950 (2015).
Schrag, D. et al. Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection. J. Natl Cancer Inst. 98, 163–171 (2006).
Kaufman, B. et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J. Clin. Oncol. 33, 244–250 (2015).
Griffiths, R. W. et al. Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube. Int. J. Gynecol. Cancer 21, 58–65 (2011).
Herzog, T. J. et al. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. Gynecol. Oncol. 132, 8–17 (2014).
Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203–213 (2003).
Hamanishi, J. et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 33, 4015–4022 (2015).
Mahoney, K. M. & Atkins, M. B. Prognostic and predictive markers for the new immunotherapies. Oncology (Williston Park) 28, 39–48 (2014)
Patch, A. M. et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 521, 489–494 (2015).
Acknowledgements
R.L.C. is supported by the Ann Rife Cox Chair in Gynecology, the Judy Reis and Albert Pisani Ovarian Cancer Research Fund, and CPRIT RP120214.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R.L.C. discloses he receives research support from AstraZeneca/MedImmune, Clovis Oncology and Roche/Genentech.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Coleman, R. Insights into strategies for optimizing ovarian cancer care. Nat Rev Clin Oncol 13, 71–72 (2016). https://doi.org/10.1038/nrclinonc.2015.225
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2015.225
This article is cited by
-
Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion
Cell Death & Disease (2022)
-
VISTA expressed in tumour cells regulates T cell function
British Journal of Cancer (2019)
-
The RNA binding protein SORBS2 suppresses metastatic colonization of ovarian cancer by stabilizing tumor-suppressive immunomodulatory transcripts
Genome Biology (2018)
